Showing 12 out of 2273 items
- The goal of this resource is to provide public health professionals, researchers, staff in provincial/territorial governments and community organizations with ...
- The pharmaceutical company Gilead Sciences has been developing combinations of anti-hepatitis C virus (HCV) drugs. One combination consists of the following two ...
- Researchers at the University of Maryland and the U.S. National Institutes of Health (NIH) have found a relatively high rate of mental health conditions among ...
- People who share equipment for substance use are at increased risk for infection with germs, including hepatitis C virus (HCV) and HIV. In the past five years, ...
- Some direct acting antivirals (DAAs) used for the treatment of hepatitis C virus (HCV), including ledipasvir (in Harvoni), require an acidic environment in the ...
- Hepatitis C virus (HCV) infects the liver, causing inflammation. If left untreated, it also results in a gradual loss of healthy tissue and its replacement with ...
- Historically, treatment for chronic hepatitis C virus (HCV) infection consisted of weekly injections of interferon accompanied by daily oral doses of the ...
- Doctors in Barcelona recently reported an unexpected increase in liver cancer recurrence in people who had been or who are being treated for chronic hepatitis C ...
- Doctors in Vienna, Austria, recently reported a group of cases of liver cancer in 19 participants whose hepatitis C virus (HCV) was treated with direct acting ...
- Spurred by reports from other cities, doctors in Bologna, Italy, have reviewed their database to assess possible risk factors for liver cancer development and ...
- As mentioned earlier in this issue of TreatmentUpdate, reports from Barcelona and Vienna have emerged suggesting that exposure to direct acting antivirals ...